相关实验视频

Updated: Sep 14, 2025

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Published on: October 13, 2023

针对METTL3/YTHDF3/m6A/PGK1轴,以对抗胆管癌的进展

Dongjie Wang¹, Chunmei Meng¹, Juan Fan¹

¹Department of Gynaecology, The First People's Hospital of Yunnan Province, Kunming, China; The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.

Archives of biochemistry and biophysics

|July 18, 2025

概括

这项研究揭示了N6 - 甲基氨酸 (m6A) RNA修饰如何稳定糖酸激酶1 (PGK1) mRNA,推动胆瘤 (CC) 的进展和糖解. 针对这种METTL3/YTHDF3/m6A/PGK1途径为CC提供了新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生化学

背景情况:

胆瘤 (CC) 是一种具有较差的代谢调节的侵袭性瘤.
糖解对于癌症生长至关重要,而糖酸激酶1 (PGK1) 是该途径中的关键酶.
N6-甲基氨酸 (m6A) RNA甲基化与瘤发生有关,但其在CC中的作用,特别是与PGK1的作用尚未研究.

研究的目的:

研究m6A修饰的PGK1在胆瘤 (CC) 进展中的作用.
为了阐明PGK1的调节机制通过m6A修改在CC.
确定PGK1作为潜在的诊断生物标志物和CC的治疗点.

主要方法:

生物信息学分析以确定CC进展和糖解中的关键调节者.
试验室内实验涉及在CC细胞系中PGK1的淘汰 (BeWo,JEG-3).
使用异种移植小鼠模型进行体内研究,以评估瘤生长抑制.
研究甲基转移酶样3 (METTL3) 和含有YTH域的家族蛋白3 (YTHDF3) 在PGK1调控中的作用.

主要成果:

生物信息学确定PGK1是CC进展和糖解中的关键调节者,在CC细胞系中观察到上调.
在体内,PGK1 knockdown抑制了CC细胞的增殖,糖解和瘤的生长.
发现METTL3/YTHDF3轴通过通过m6A修饰增加PGK1mRNA稳定性并促进其翻译来增强CC进展.
过度表达METTL3或YTHDF3部分挽救了PGK1沉默的效果,恢复了PGK1表达和糖溶性功能.

结论:

METTL3/YTHDF3/m6A/PGK1通路通过稳定PGK1mRNA并增强糖解,显著促进胆 ?? 瘤的进展.
PGK1是CC瘤发生的关键调解者,是潜在的诊断生物标志物.
针对METTL3/YTHDF3/m6A/PGK1轴为胆瘤治疗提供了一个有前途的治疗策略.

关键词:

胆 ?? 瘤是一种胆 ?? 瘤.葡萄糖溶解是什么? 葡萄糖溶解通过N6-甲基氨酸甲基化.一个PGK1的PGK1

更多相关视频

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

CAM-Delam Assay to Score Metastatic Properties by Quantifying Delamination and Invasion Capacity of Cancer Cells

Published on: June 2, 2022

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...